Cargando…
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This artic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503649/ https://www.ncbi.nlm.nih.gov/pubmed/31118733 http://dx.doi.org/10.2147/CCID.S165605 |
_version_ | 1783416445753884672 |
---|---|
author | Galluzzo, M D’Adamio, S Massaro, A Piccolo, A Bianchi, L Talamonti, M |
author_facet | Galluzzo, M D’Adamio, S Massaro, A Piccolo, A Bianchi, L Talamonti, M |
author_sort | Galluzzo, M |
collection | PubMed |
description | The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab). |
format | Online Article Text |
id | pubmed-6503649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65036492019-05-22 Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date Galluzzo, M D’Adamio, S Massaro, A Piccolo, A Bianchi, L Talamonti, M Clin Cosmet Investig Dermatol Review The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab). Dove 2019-05-01 /pmc/articles/PMC6503649/ /pubmed/31118733 http://dx.doi.org/10.2147/CCID.S165605 Text en © 2019 Galluzzo et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Galluzzo, M D’Adamio, S Massaro, A Piccolo, A Bianchi, L Talamonti, M Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date |
title | Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date |
title_full | Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date |
title_fullStr | Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date |
title_full_unstemmed | Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date |
title_short | Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date |
title_sort | spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503649/ https://www.ncbi.nlm.nih.gov/pubmed/31118733 http://dx.doi.org/10.2147/CCID.S165605 |
work_keys_str_mv | AT galluzzom spotlightonbrodalumabinthetreatmentofplaquepsoriasistheevidencetodate AT dadamios spotlightonbrodalumabinthetreatmentofplaquepsoriasistheevidencetodate AT massaroa spotlightonbrodalumabinthetreatmentofplaquepsoriasistheevidencetodate AT piccoloa spotlightonbrodalumabinthetreatmentofplaquepsoriasistheevidencetodate AT bianchil spotlightonbrodalumabinthetreatmentofplaquepsoriasistheevidencetodate AT talamontim spotlightonbrodalumabinthetreatmentofplaquepsoriasistheevidencetodate |